Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jun;47(6):1457-1465.
doi: 10.1007/s40618-023-02257-3. Epub 2024 Jan 12.

Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy

Affiliations
Observational Study

Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy

M Arosio et al. J Endocrinol Invest. 2024 Jun.

Abstract

Objective: This study aimed to assess the long-term outcome of patients with acromegaly.

Design: This is a multicenter, retrospective, observational study which extends the mean observation period of a previously reported cohort of Italian patients with acromegaly to 15 years of follow-up.

Methods: Only patients from the centers that provided information on the life status of at least 95% of their original cohorts were included. Life status information was collected either from clinical records or from the municipal registry offices. Standardized mortality ratios (SMRs) were computed comparing data with those of the general Italian population.

Results: A total of 811 patients were included. There were 153 deaths, with 90 expected and an SMR of 1.7 (95% CI 1.4-2.0, p < 0.001). Death occurred after a median of 15 (women) or 16 (men) years from the diagnosis, without gender differences. Mortality remained elevated in the patients with control of disease (SMR 1.3, 95% CI 1.1-1.6). In the multivariable analysis, only older age and high IGF1 concentrations at last available follow-up visit were predictors of mortality. The oncological causes of death outweighed the cardiovascular ones, bordering on statistical significance with respect to the general population.

Conclusions: Mortality remains significantly high in patients with acromegaly, irrespectively of disease status, as long as the follow-up is sufficiently long with a low rate of patients lost to follow-up. Therapy strategy including radiotherapy does not have an impact on mortality. Oncological causes of death currently outweigh the cardiovascular causes.

Keywords: Acromegaly; Epidemiology; IGF1; Mortality; Therapy.

PubMed Disclaimer

Conflict of interest statement

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Similar articles

  • Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy).
    Colao A, Vandeva S, Pivonello R, Grasso LF, Nachev E, Auriemma RS, Kalinov K, Zacharieva S. Colao A, et al. Eur J Endocrinol. 2014 Aug;171(2):263-73. doi: 10.1530/EJE-13-1022. Epub 2014 May 30. Eur J Endocrinol. 2014. PMID: 24878680
  • Predictors of morbidity and mortality in acromegaly: an Italian survey.
    Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M; Italian Study Group of Acromegaly. Arosio M, et al. Eur J Endocrinol. 2012 Aug;167(2):189-98. doi: 10.1530/EJE-12-0084. Epub 2012 May 17. Eur J Endocrinol. 2012. PMID: 22596288
  • Mortality in acromegaly: a 20-year follow-up study.
    Ritvonen E, Löyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, Kauppinen-Mäkelin R, Schalin-Jäntti C. Ritvonen E, et al. Endocr Relat Cancer. 2016 Jun;23(6):469-80. doi: 10.1530/ERC-16-0106. Epub 2016 May 16. Endocr Relat Cancer. 2016. PMID: 27185871
  • [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
    Zona A, Fazzo L, Benedetti M, Bruno C, Vecchi S, Pasetto R, Minichilli F, De Santis M, Nannavecchia AM, Di Fonzo D, Contiero P, Ricci P, Bisceglia L, Manno V, Minelli G, Santoro M, Gorini F, Ancona C, Scondotto S, Soggiu ME, Scaini F, Beccaloni E, Marsili D, Villa MF, Maifredi G, Magoni M, Iavarone I; Gruppo di lavoro SENTIERI 2019-2022. Zona A, et al. Epidemiol Prev. 2023 Jan-Apr;47(1-2 Suppl 1):1-286. doi: 10.19191/EP23.1-2-S1.003. Epidemiol Prev. 2023. PMID: 36825373 Italian.
  • GH and mortality in acromegaly.
    Sheppard MC. Sheppard MC. J Endocrinol Invest. 2005;28(11 Suppl International):75-7. J Endocrinol Invest. 2005. PMID: 16625851 Review.

Cited by

References

    1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Investig. 2009;119(11):3189–3202. doi: 10.1172/JCI39375. - DOI - PMC - PubMed
    1. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. 10.1210/jc.2014-2700 - PubMed
    1. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9. doi: 10.1007/s11102-016-0754-x. - DOI - PMC - PubMed
    1. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332. doi: 10.1210/er.2018-00115. - DOI - PubMed
    1. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39(153):1–16. - PubMed

Publication types